LAG3 and cervical small cell carcinoma: It is noteworthy that FGL1,19 a novel ligand of LAG‐3, is upregulated in patients with less leucocyte infiltration and lower PD‐1 signals, indicating that FGL1‐LAG3 might be another significant immunotherapy target for SCCE irresponsive to PD‐1/PD‐L1 blockade.